Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial(*)
However, the full effects may take longer to manifest, and results can vary depending on individual factors such as lifestyle, diet, and overall health
Its formula focuses on appetite regulation, metabolic efficiency, and fat utilization rather than temporary energy spikes
The Bottom Line Microdosing GLP-1 reflects a real patient concern: balancing effectiveness, tolerability, cost, and long-term planning
If you have type 2 diabetes, your provider may choose a medication and dose that offers the best combination of blood sugar control and weight loss
We do not use peptides as standalone magic bullets